# 2026-14672: FDA Gives Public Extra Time to Weigh In on Drug Pilot

2026-14672, Expedited Investigational New Drug Pilot Program; Request for Information; Extension of the Comment Period, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-07-21, effective 2026-08-24 (as of 2026-07-28).

- Canonical: https://policyrisk.com/federal-register/2026-14672
- As of: 2026-07-28
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-14672
- Title: Expedited Investigational New Drug Pilot Program; Request for Information; Extension of the Comment Period
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 45820
- Published: 2026-07-21
- Effective: 2026-08-24
- Comments close: 2026-08-24
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-07-28

## In one line

FDA Gives Public Extra Time to Weigh In on Drug Pilot

## Summary

The FDA is giving everyone more time to share their thoughts on a new pilot program that aims to speed up how quickly new drugs can start human testing, while keeping safety a top priority. This affects drug makers, researchers, and patients waiting for new treatments. Comments are now due by August 24, 2026, so don’t miss your chance to weigh in on this exciting change!

## Abstract

The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice that appeared in the Federal Register of June 24, 2026, to open a public docket to solicit input and comments on a proposal to establish a pilot program, the Expedited Investigational New Drug (IND) pilot program, to shorten the time it takes from drug identification to first-in-human (FIH) study, while protecting clinical trial participants.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2026-14672 on federalregister.gov](https://www.federalregister.gov/documents/2026/07/21/2026-14672/expedited-investigational-new-drug-pilot-program-request-for-information-extension-of-the-comment)
- [2026-14672 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-07-21/pdf/2026-14672.pdf)

## Related
- [Previous: 2026-14669, Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holdin…](https://policyrisk.com/federal-register/2026-14669)
- [Next: 2026-14674, Sunshine Act Meeting; Open Commission Meeting Wednesday, July 22, 2026](https://policyrisk.com/federal-register/2026-14674)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-14672 (as of 2026-07-28).